Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 0.500. It has been cited 27 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.500
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: P30 CA016086
NCI NIH HHS
Grant: P30 CA014236
NHLBI NIH HHS
Grant: R01 HL155098
NCI NIH HHS
Grant: T32 CA211056
NCI NIH HHS
Grant: R37 CA247676
NCI NIH HHS
Grant: P50 CA058223
NIGMS NIH HHS
Grant: K12 GM000678
National Institutes of Health
Grant: 3P30CA016086-42S2
Cancer Center Support Grant
National Institutes of Health
Grant: 5P50CA058223-12
SPORE in Breast Cancer
V Foundation for Cancer Research
UNC University Cancer Research Fund
Merck & Co., Inc.
Translating Duke Health
Susan G. Komen for the Cure
FWCI
2.24
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals